Anvumetostat

Anvumetostat
INN: anvumetostat
Clinical data
Other names	AMG-193
Identifiers
	IUPAC name (4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]methanone;
CAS Number	2790567-82-5;
PubChem CID	164536956;
UNII	QAT649EJ5E;
ChEMBL	ChEMBL6134011;
PDB ligand	A1ATH (PDBe, RCSB PDB);
Chemical and physical data
Formula	C22H19F3N4O3
Molar mass	444.414 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COC[C@@H](N1C(=O)C2=NC=C3C(=C2)C4=C(COC4)C(=N3)N)C5=CC=C(C=C5)C(F)(F)F;
	InChI InChI=InChI=1S/C22H19F3N4O3/c23-22(24,25)13-3-1-12(2-4-13)19-11-31-6-5-29(19)21(30)17-7-14-15-9-32-10-16(15)20(26)28-18(14)8-27-17/h1-4,7-8,19H,5-6,9-11H2,(H2,26,28)/t19-/m1/s1; Key:BFEBTMFPRJPBTK-LJQANCHMSA-N;

Anvumetostat is an investigational new drug that is being developed by Amgen for the treatment of methylthioadenosine phosphorylase (MTAP)-null solid tumors.^[1] Anvumetostat acts as a PRMT5 inhibitor.^[2]^[3]^[4]^[5]

References

↑ "Anvumetostat". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ "anvumetostat". Cancer.gov. U.S. National Cancer Institute.
↑ Pettus LH, Bourbeau M, Tamayo NA, Amegadzie A, Beylkin D, Booker SK, et al. (April 2025). "Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers". Journal of Medicinal Chemistry. 68 (7): 6932–6954. doi:10.1021/acs.jmedchem.4c03121. PMID 40146197.
↑ Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, et al. (January 2025). "AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers". Cancer Discovery. 15 (1): 139–161. doi:10.1158/2159-8290.CD-24-0887. PMC 11726016. PMID 39282709.
↑ Rodon J, Johnson ML, George B, Shah PA, Arbour KC (April 2026). "MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario". Cancer Research. 86 (7): 1558–1569. doi:10.1158/0008-5472.CAN-25-2126. PMC 13044523. PMID 41512197.